Transgene (LTS:0OCQ) Long-Term Capital Lease Obligation : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Transgene Long-Term Capital Lease Obligation?

Transgene's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil.

Transgene's quarterly Long-Term Capital Lease Obligation declined from Dec. 2023 (€0.02 Mil) to Jun. 2024 (€0.00 Mil) but then stayed the same from Jun. 2024 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Transgene's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (€1.26 Mil) to Dec. 2023 (€0.02 Mil) and declined from Dec. 2023 (€0.02 Mil) to Dec. 2024 (€0.00 Mil).

Transgene Long-Term Capital Lease Obligation Historical Data

The historical data trend for Transgene's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Long-Term Capital Lease Obligation Chart

Transgene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

3.74

2.45

1.26

0.02

Transgene Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.26	0.09	0.02	-	-

Transgene (LTS:0OCQ) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Transgene Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Transgene's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TRGNF:USA TNG:France TGNA:Germany

Address

400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Transgene Headlines

No Headlines